Phoenix Rising Treatment

Phoenix Rising Treatment (Mount Holly, NJ) is a SAMHSA Behavioral Health Treatment Services Locator-registered facility. The facility's programming is outpatient (IOP, Dual Dx), not residential. Evaluation of this facility against current clinical standards should encompass ASAM 4e framework alignment, MAT policy, and payer-specific network status.

Care levels at Phoenix Rising Treatment

Phoenix Rising Treatment is an outpatient-focused program (IOP, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care Phoenix Rising Treatment provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Payment and insurance posture: Phoenix Rising Treatment accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Specialty programming

The facility's documented specialty programming includes: Clients with co-occurring mental and substance use disorders, Clients who have experienced trauma. Specialty-program verification requires review of: (a) dedicated specialty-track programming hours per week; (b) specialty-credentialed clinical staffing (e.g., LCSW with trauma specialization, perinatal-nurse certification, adolescent-development training); (c) specialty-specific clinical assessment protocols; (d) specialty-specific outcome measurement. Marketing designation alone is insufficient for clinical confidence.

Before you call

Pre-admission due-diligence for Phoenix Rising Treatment: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via NJ behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Phoenix Rising Treatment offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.